

## Publications, reviews, book chapters – Prof. Dr. A. Buschauer

1. Buschauer, A.; Sattler, H.-J.; Schunack, W. Synthese von 2-(2-Aminoethyl)-4-hydroxymethylimidazol. *Arch. Pharm.* **1982**, *315*, 563-566.
2. Buschauer, A.; Wegner, K.; Schunack, W. Basisch substituierte Cimetidin-Analoga. *Eur. J. Med. Chem. - Chim. Ther.* **1982**, *17*, 505-508.
3. Buschauer, A.; Schunack, W. Die Struktur des N(pi)-Methylisohistamins - Eine Richtigstellung. *Arch. Pharm.* **1983**, *316*, 891-894.
4. Buschauer, A.; Wegner, K.; Schunack, W. 1,n-Bis(2-imidazolyl)alkane. *Arch. Pharm.* **1983**, *316*, 515-520.
5. Elz, S.; Buschauer, A.; Dräger, M.; Schunack, W. Darstellung, Eigenschaften und Kristallstruktur der N-[2-(4,5,6,7-Tetrahydro-2-benzimidazolyl)ethyl]phthalamidsäure. *Z. Naturforsch.* **1983**, *38b*, 1203-1207.
6. Buschauer, A.; Sattler, H.-J.; Schunack, W. 7,8-Dihydroimidazo[1,2-c]pyrimidin-5(6H)-one, -5(6H)-thione und -5(6H)-yliden-cyanamide. *Chem. Ber.* **1984**, *117*, 2597-2614.
7. Buschauer, A.; Schunack, W. (8,9-Dihydro-7H-imidazo[1,2-c][1,3]diazepin-H)-one, -5(6H)-thione und -5(6H)-yliden-cyanamide. *J. Heterocycl. Chem.* **1984**, *21*, 753-757.
8. Buschauer, A.; Wegner, K.; Schunack, W. Isohistamine. *Arch. Pharm.* **1984**, *317*, 9-14.
9. Buschauer, A. 4-Aminopyrimidine mit H<sub>2</sub>-antihistaminischer Aktivität. *Pharm. Ztg. Sci. Ed.* **1985**, *130*, 2067-2070.
10. Buschauer, A.; Postius, S.; Szelenyi, I.; Schunack, W. Isohistamine und Homologe als Bausteine von H<sub>2</sub>-Antagonisten. *Arzneim.-Forsch.* **1985**, *35*, 1025-1029.
11. Buschauer, A.; Schunack, W. Isocimetidin und Analoga. *Arzneim.-Forsch.* **1985**, *35*, 1223-1224.
12. Schunack, W.; Buschauer, A.; Büyüktimkim, S.; Dziuron, P.; Elz, S.; Gerhardt, G.; Lebenstedt, E.; Lennartz, H.-G.; Schwarz, S.; Spitzhoff, M.; Steffens, R., Histamine agonists - chemistry and structure-activity relationships. In *VIIIth International Symposium on Medicinal Chemistry*, Dahlbom, R.; Nilsson, J. L. G., Eds. Swedish Pharmaceutical Press: Stockholm, **1985**, 169-182.
13. Buschauer, A.; Krämer, I.; Schunack, W. Synthese und H<sub>2</sub>-antagonistische Wirkung 3-(3-piperidinomethyl-phenoxy)propyl-substituierter Kohlensäurederivate und Analoga. *Arch. Pharm.* **1986**, *319*, 434-443.
14. Mohr, R.; Buschauer, A.; Schunack, W. 1,3,5-Triazin-2,4-diamine und -2,4,6-triamine mit H<sub>2</sub>-antagonistischer Wirkung. *Arch. Pharm.* **1986**, *319*, 878-885.
15. Baumann, G.; Permanetter, B.; Buschauer, A.; Wirtzfeld, A.; Schunack, W., Mögliche Bedeutung einer kardialen H<sub>2</sub>-Rezeptor Stimulation bei Katecholamin-refraktärem Myokardversagen unterschiedlicher Ätiologie. In *Autonome Innervation des Herzens - Myokardiale Hypoxie*, Brisse, B.; Bender, F., Eds. Steinkopff-Verlag: Darmstadt, **1987**, 183-194.

16. Buschauer, A. Arylmethylthioalkylguanidin-Derivate, Synthese und pharmakologische Wirkung. *Arzneim.-Forsch.* **1987**, 37, 1008-1012.
17. Buschauer, A. Synthese und pharmakologische Wirkung substituierter Imidazolylalkyl- und Thiazolylalkylguanidine. *Arzneim.-Forsch.* **1987**, 37, 1003-1007.
18. Buschauer, A. Synthese von N-Benzoyl- und N-Methansulfonyl-diphenylimidocarbonat. *Arch. Pharm.* **1987**, 320, 377-378.
19. Baumann, G.; Buschauer, A.; Permanetter, B.; Schunack, W. Neue Aspekte zur Therapie der Myokardinsuffizienz. *Inn. Med.* **1988**, 15, 30-38.
20. Buschauer, A. Synthese positiv inotroper Substanzen: Imidazolylpropylguanidine mit Pyridin-Partialstruktur. *Arch. Pharm.* **1988**, 321, 415-418.
21. Buschauer, A. Synthese positiv inotroper Substanzen: Aryloxyalkylguanidine. *Arch. Pharm.* **1988**, 321, 281-285.
22. Buschauer, A. Imidazolylalkylguanidine mit Diaryl-Partialstrukturen. *Sci. Pharm.* **1988**, 56, 81-88.
23. Buschauer, A. Phenoxy- and Phenylthioalkylguanidines - Synthesis and in vitro Pharmacology. *Eur. J. Med. Chem.* **1988**, 23, 1-6.
24. Büyüktimkim, N.; Buschauer, A. Separation and Determination of some Amino Acid Ester Enantiomers on TLC after Derivatization with Activated (S)-(+)-Naproxen. *J. Chromatogr.* **1988**, 450, 281-283.
25. Büyüktimkin, S.; Buschauer, A.; Schunack, W. Synthese von 1-(Aminoalkyl)-2-aryl-2,3-dihydro-4(1H)-chinazolinonen. *Arch. Pharm.* **1988**, 321, 833-834.
26. Elz, S.; Kimmel, U.; Buschauer, A.; Schunack, W. Halogenderivate von N-[3-(Imidazol-4-yl)propyl]-N'-(2-phenylthioalkyl)guanidinen. *Sci. Pharm.* **1988**, 56, 229-234.
27. Keller, F.; Buschauer, A.; Schunack, W. Synthese, Racemattrennung und pharmakologische Wirkung chiraler H<sub>2</sub>-Antagonisten vom Aminomethylphenoxypropylamin-Typ. *Pharm. Ztg. Wiss.* **1988**, 1/113, 48-55.
28. Mohr, R.; Buschauer, A.; Schunack, W. Basisch substituierte Aryloxyalkylguanidine und Analoge mit H<sub>2</sub>-antagonistischer Wirkung. *Arch. Pharm.* **1988**, 321, 221-227.
29. Baumann, G.; Buschauer, A.; Permanetter, B.; Schunack, W., Wiederherstellung der b<sub>1</sub>-adrenergen Ansprechbarkeit bei Patienten mit Myokardinsuffizienz. In *Katecholamine in der Notfall- und Intensivmedizin*, Löllgen, H.; Just, H.; Meinertz, T., Eds. Perimed Verlag: Erlangen, **1989**, 28-42.
30. Burde, R.; Seifert, R.; Buschauer, A.; Schultz, G. Histamine inhibits activation of human neutrophils and HL-60 leukemic cells via H<sub>2</sub>-receptors. *Naunyn-Schmiedeberg's archives of pharmacology* **1989**, 340, 671-678.
31. Buschauer, A. Synthesis and in vitro pharmacology of arpromidine and related Phenylpyridyl-alkyl-guanidines, a potential new class of positive inotropic drugs. *J. Med. Chem.* **1989**, 32, 1963-1970.
32. Buschauer, A. Entwicklung neuer positiv inotroper Arzneistoffe: Suche nach einem Digitalisersatz. *Pharm. Ztg. Wiss.* **1989**, 2/134, 3-16.

33. Buschauer, A. Zur Synthese primärer w-Phenyl-w-pyridylalkylamine. *Arch. Pharm.* **1989**, *322*, 165-171.
34. Buschauer, A.; Schunack, W.; Arrang, J.-M.; Garbarg, M., Histamine Receptors. In *Receptor Pharmacology and Function*, Williams, M.; Glennon, R. A.; Timmermans, P. B. M. W. M., Eds. Marcel Dekker Inc.: New York, **1989**, Vol. 13, 293-347.
35. Büyüktimkin, S.; Buschauer, A.; Schunack, W. Synthese und pharmakologische Aktivität von 2-Aryl-1-((3-(imidazol-4-yl)propyl)guanidinoalkyl)-2,3-dihydro-4(1H)-chinazolinonen. *Arch. Pharm.* **1989**, *322*, 115-118.
36. Pawlowski, M.; Buschauer, A.; Schunack, W. Synthesis of Some 9-(Aminoalkyl)-6,7-dihydropyrimido[2,1-f]purine-2,4,8-(1H,3H,9H)-triones. *Arch. Pharm.* **1989**, *322*, 447-449.
37. Burde, R.; Buschauer, A.; Seifert, R. Characterization of histamine H<sub>2</sub>-receptors in human neutrophils with a series of guanidine analogues of impromidine: Are cell type-specific H<sub>2</sub>-receptors involved in the regulation of NADPH oxidase? *Naunyn-Schmiedeberg's Archives of Pharmacology* **1990**, *341*, 455-461.
38. Meindl, W.; Friese-Kimmel, A.; Lachenmayr, F.; Buschauer, A.; Schunack, W. Der Einfluß von Agonisten und Antagonisten des Histamin-H<sub>1</sub>- und H<sub>2</sub>-Rezeptors auf das Wachstum von *Mycobacterium tuberculosis* H 37 Ra. *Arch. Pharm.* **1990**, *323*, 267-272.
39. Mörsdorf, P.; Engler, H.; Schickaneder, H.; Buschauer, A.; Schunack, W.; Baumann, G. Cardiohistaminergics - new developments in histamine H<sub>2</sub>-agonists. *Drugs of the Future* **1990**, *15*, 919-933.
40. Ruat, M.; Traiffort, E.; Bouthenet, M. L.; Schwartz, J.-C.; Hirschfeld, J.; Buschauer, A.; Schunack, W. Reversible and irreversible labeling and autoradiographic localization of the cerebral histamine H<sub>2</sub>-receptor. *Proc. Natl. Acad. Sci. USA* **1990**, *87*, 1658-1662.
41. Buschauer, A.; Baumann, G. Structure-activity relationships of histamine H<sub>2</sub>-agonists, a new class of positive inotropic drugs. *Agents Actions Suppl.* **1991**, *33*, 231-256.
42. Buschauer, A.; Lachenmayr, F.; Schunack, W. Synthesis and histamine H<sub>2</sub>-agonistic activity of ring-substituted phenyl analogues of impromidine. *Pharmazie* **1991**, *46*, 841-845.
43. Büyüktimkin, S.; Buschauer, A.; Schunack, W. Synthese und H<sub>1</sub>/H<sub>2</sub>-antihistaminische Wirkung w-[2-Aryl-2,3-dihydro-4(1H)-chinazolinon-1-yl]alkyl-substituierter Harnstoffe und Cyanoguanidine. *Arch. Pharm.* **1991**, *324*, 291-295.
44. Felix, S. B.; Buschauer, A.; Baumann, G. Therapeutic value of H<sub>2</sub>-receptor stimulation in congestive heart failure. Hemodynamic effects of BU-E-76, BU-E-75 and arpromidine (BU-E-50) in comparison to impromidine. *Agents Actions Suppl.* **1991**, *33*, 257-269.
45. Klein-Tebbe, J.; Schramm, J.; Bolz, M.; Gagné, H.; Josties, C.; Lipp, R.; Friese, A.; Stark, H.; Zingel, V.; Buschauer, A.; Fricker, G., Influence of histamine H<sub>1</sub>, H<sub>2</sub>, and H<sub>3</sub> agonists and antagonists on IgE mediated histamine release from human basophils. In *New Trends in Allergy III*, Ring, J.; Przbilla, B., Eds. Springer: Berlin Heidelberg, **1991**, 152-157.
46. Ruat, M.; Traiffort, E.; Bouthenet, M. L.; Pollard, H.; Moreau, J.; Schwartz, J.-C.; Martinez-Mir, I.; Palacios, J. M.; Hirschfeld, J.; Buschauer, A.; Schunack, W.; Tertuik, W.; Ganellin, C. R. Reversible and irreversible labelling of H<sub>1</sub>- and H<sub>2</sub>-receptors using novel [<sup>125</sup>I]probes. *Agents Actions Suppl.* **1991**, *33*, 123-144.

47. Baumann, G.; Buschauer, A.; Felix, S. B. Hemodynamic profile of arpromidine and its F<sub>2</sub>-substituted derivatives in comparison to impromidine in congestive heart failure. *Agents Actions* **1992**, *Special Co*, C329-C332.
48. Bungardt, E.; Buschauer, A.; Moser, U.; Schunack, W.; Lambrecht, G.; Mutschler, E. Histamine H<sub>1</sub>-receptors mediate vasodilation in guinea-pig ileum resistance vessels: Characterization by the use of computer-assisted videomicroscopy and new selective agonists. *Eur. J. Pharmacol.* **1992**, *221*, 91-98.
49. Buschauer, A.; Baumann, G., H<sub>2</sub>-Agonisten des Arpromidin-Typs: Neue potentielle Arzneistoffe zur Behandlung der Herzinsuffizienz. In *Entzündung und verwandte Reaktionen - Neue Erkenntnisse, neue Wirkstoffe*, Hirschelmann, R., Ed. Jenapharm: Jena, 1992; pp 192-203.
50. Buschauer, A.; Friese-Kimmel, A.; Baumann, G.; Schunack, W. Synthesis and histamine H<sub>2</sub> agonistic activity of arpromidine analogues: replacement of the pheniramine-like moiety by non-heterocyclic groups. *Eur. J. Med. Chem.* **1992**, *27*, 321-330.
51. Buschauer, A.; Lachenmayr, F.; Schunack, W. Synthesis and histamine H<sub>2</sub>-receptor activity of heterocyclic impromidine analogues. *Pharmazie* **1992**, *47*, 86-91.
52. Franke, R.; Buschauer, A. Quantitative structure-activity relationships in histamine H<sub>2</sub>-agonists related to impromidine and arpromidine. *Eur. J. Med. Chem.* **1992**, *27*, 443-448.
53. Hirschfeld, J.; Buschauer, A.; Elz, S.; Schunack, W.; Ruat, M.; Traiffort, E.; Schwartz, J.-C. Iodoaminopotentidine and related compounds: a new class of ligands with high affinity and selectivity for the histamine H<sub>2</sub>-receptor. *J. Med. Chem.* **1992**, *35*, 2231-2238.
54. Klein-Tebbe, J.; Buschauer, A.; Friese, A.; Schunack, W.; Kunkel, G. Modulation of IgE-mediated histamine release from human leukocytes by a new class of histamine H<sub>2</sub>-agonists. *Agents Actions* **1992**, *35*, 185-191.
55. Michel, M. C.; Buschauer, A. Neuropeptide Y and its antagonists. *Drugs Fut.* **1992**, *17*, 39-45.
56. Seifert, R.; Höer, A.; Offermann, S.; Buschauer, A.; Schunack, W. Histamine increases Ca<sup>2+</sup> in dibutyryl cyclic AMP-differentiated HL-60 cells via H<sub>1</sub>-receptors and is an incomplete secretagogue. *Mol. Pharmacol.* **1992**, *42*, 227-234.
57. Seifert, R.; Höer, A.; Schwaner, I.; Buschauer, A. Histamine increases cytosolic Ca<sup>2+</sup> in HL-60 promyelocytes predominantly via H<sub>2</sub>-receptors with an unique agonist/antagonist profile and induces functional differentiation. *Molecular Pharmacology* **1992**, *42*, 235-241.
58. Sellier, C.; Elz, S.; Buschauer, A.; Schunack, W. The effect of lipophilic substituents on the H<sub>2</sub>-histaminergic activity of some close analogues of impromidine. *Arch. Pharm.* **1992**, *325*, 471-476.
59. Sellier, C.; Elz, S.; Buschauer, A.; Schunack, W. Zur Synthese von (Z)- und (E)-3-(1H-imidazol-4-yl)-2-propenamin und einigen 3-(1H-Imidazol-4-yl)propanaminen. *Liebigs Ann. Chem.* **1992**, *1992*, 317-322.
60. Sellier, C.; Elz, S.; Buschauer, A.; Schunack, W. Histamine analogues: imidazolylalkylguanidines, synthesis and in vitro pharmacology. *Eur. J. Med. Chem.* **1992**, *27*, 27-32.
61. Buschauer, A. Diuretika - eine chemisch-pharmakologische Betrachtung. *Pharm. Ztg.* **1993**, *138*, 177-188.

62. Franke, R.; Buschauer, A., Interaction terms in Free-Wilson analysis: A QSAR of histamine H<sub>2</sub>-agonists. In *Trends in QSAR and Molecular Modelling 92*, Wermuth, C. G., Ed. Escom: Leiden, 1993; pp 160-162.
63. Stinner, B.; Hasse, C.; Lorenz, W.; Alisch, R.; Schulze, F.; Sitter, H.; Lüdke, U.; Buschauer, A.; Schunack, W. Effects of drugs combining H<sub>1</sub> and H<sub>2</sub> receptor antagonist activity on histamine release and life threatening anaphylactoid reactions in pigs. *Agents Actions* **1993**, *38, Specia*, C286-C288.
64. Baumann, G.; Buschauer, A.; Felix, S. B., Mögliche therapeutische Bedeutung sarkolemmaler Histamin-H<sub>2</sub>-Rezeptoren bei Herzinsuffizienz: Hämodynamische Effekte neuer H<sub>2</sub>-Agonisten. In *Pathobiochemie, Molekularbiologie und moderne Diagnostik kardiovaskulärer Erkrankungen*, Greiling, H., Ed. Springer: Berlin Heidelberg, 1994; pp 104-115.
65. Kleine-Tebbe, J.; Josties, C.; Frank, G.; Stalleicken, D.; Buschauer, A.; Schunack, W. Inhibition of IgE- and non-IgE-mediated histamine release from human basophil leukocytes in vitro by a histamine H<sub>1</sub>-antagonist, desethoxycarbonyl-loratadine. *J. Allergy Clin. Immunol.* **1994**, *93*, 494-500.
66. Rixen, D.; Neugebauer, E.; Lechleuthner, A.; Buschauer, A.; Nagelschmidt, M.; Thoma, S.; Rink, A. Beneficial effect of H<sub>2</sub>-agonism and H<sub>1</sub>-antagonism in rat endotoxic shock ? *Shock* **1994**, *2*, 47-52.
67. Schulze, F. R.; Alisch, R. A.; Buschauer, A.; Schunack, W. Synthese und kombinierte H<sub>1</sub>-/H<sub>2</sub>-antagonistische Aktivität von Mepyramin- Pheniramin- und Cyclizin-Derivaten mit Cyanoguanidin-, Harnstoff- und Nitroethendiamin-Partialstrukturen. *Arch. Pharm.* **1994**, *327*, 455-462.
68. Buschauer, A.; Mohr, R.; Schunack, W. Synthesis and histamine H<sub>2</sub>-receptor antagonist activity of 4-(1-pyrazolyl)butanamides, guanidinopyrazoles, and related compounds. *Arch. Pharm.* **1995**, *328*, 349-358.
69. Coruzzi, G.; Adami, M.; Pozzoli, C.; Buschauer, A.; Bertaccini, G. Different activities of impromidine and related phenyl-(pyridylalkyl)guanidines at cardiac and gastric H<sub>2</sub> receptors. *Inflamm. Res.* **1995**, *44*, 108-109.
70. Felix, S. B.; Buschauer, A.; Baumann, G. Haemodynamic profile of new H<sub>2</sub>-receptor agonists in congestive heart failure. *European Journal Of Clinical Investigation* **1995**, *25*, 42-46.
71. Glaß, D.; Buschauer, A.; Tenor, H.; Bartel, S.; Will-Shahab, L.; Krause, E.-G. 4-(4-Guanidinobenzoyl)-2-imidazolones and related compounds: Phosphodiesterase inhibitors and novel cardiotonics with combined histamine H<sub>2</sub> receptor agonist and PDE III inhibitor activity. *Arch. Pharm.* **1995**, *328*, 709-719.
72. Hagelüken, A.; Burde, R.; Nürnberg, B.; Harhammer, R.; Buschauer, A.; Seifert, R. Cationic-amphiphilic arpromidine-derived guanidines and a histamine trifluoromethyl-toluidide derivative may activate pertussis toxin-sensitive G-proteins by a receptor-independent mechanism. *Naunyn Schmiedeberg's Arch. Pharmacol.* **1995**, *351*, 305-308.
73. Knieps, S.; Michel, M. C.; Dove, S.; Buschauer, A. Non-peptide neuropeptide Y antagonists derived from the histamine H<sub>2</sub> agonist arpromidine: Role of the guanidine group. *Bioorg. Med. Chem. Lett.* **1995**, *5*, 2065-2070.
74. Knieps, S.; Dove, S.; Michel, M. C.; Rottmeier, K.; Wernet, W.; Bernhardt, G.; Buschauer, A. w -Phenyl-w -(2-pyridyl)alkyl-substituted bisguanidines are moderate neuropeptide Y antagonists. *Pharm. Pharmacol. Lett.* **1996**, *6*, 27-30.

75. Muckenschnabel, I.; Bernhardt, G.; Spruß, T.; Buschauer, A. Hyaluronidase pretreatment produces selective melphalan enrichment in malignant melanoma implanted in nude mice. *Cancer Chemother. Pharmacol* **1996**, *38*, 88-94.
76. Buschauer, A. Pharmakotherapie der Tuberkulose: Wirkmechanismen und Resistenzen. *Pharm. Ztg.* **1997**, *142*, 209-223.
77. Dove, S.; Buschauer, A. Stepwise leave-one-isomer-out Free-Wilson approaches as preprocessing tools in QSAR analysis of racemates. *Quant. Struct.-Act. Relat.* **1997**, *16*, 11-19.
78. Muckenschnabel, I.; Bernhardt, G.; Spruß, T.; Buschauer, A. A versatile HPLC method for the measurement of melphalan tailored to the optimization of hyperthermic isolated limb perfusion. *Eur. J. Pharm. Sci.* **1997**, *5*, 129-137.
79. Müller, M.; Knieps, S.; Geßele, K.; Dove, S.; Bernhardt, G.; Buschauer, A. Synthesis and neuropeptide Y Y1 receptor antagonistic activity of N,N-disubstituted w -guanidino- and w -aminoalkanoic acid amides. *Arch. Pharm. - Pharm. Med. Chem. (Weinheim)* **1997**, *330*, 333-342.
80. Schuster, A.; Bernhardt, G.; Buschauer, A. Determination of the apromidine-type histamine H<sub>2</sub>-receptor agonist N1-[3-(3,4-difluoro-phe-nyl)-3-(2-pyridyl)propyl]-N2-[3-(1H-imidazol-4-yl)propyl]guanidine and corresponding N3-alkoxycarbonylguanidines by HPLC and CE. *Eur. J. Pharm. Sci.* **1997**, *5*, 79-88.
81. Weiss, T.; Bernhardt, G.; Buschauer, A.; Jauch, K.-W.; Zirngibl, H. High-resolution RP HPLC analysis of polyamines and their monoacetyl conjugates by fluorescence detection after derivatization with N-hydroxy-succinimidyl 6-quinolinyl carbamate. *Anal. Biochem* **1997**, *247*, 294-304.
82. Aiglstorfer, I.; Uffrecht, A.; Geßele, K.; Moser, C.; Schuster, A.; Merz, S.; Malawska, B.; Bernhardt, G.; Dove, S.; Buschauer, A. NPY Y<sub>1</sub> antagonists: structure-activity relationships of arginine derivatives and hybrid compounds with apromidine-like partial structures. *Regul. Pept.* **1998**, *75*, 75-76.
83. Dove, S.; Buschauer, A. Imidazolylpropylguanidines as histamine H<sub>2</sub> receptor agonists: 3D-QSAR of a large series. *Pharm. Acta Helv.* **1998**, *73*, 145-155.
84. Muckenschnabel, I.; Bernhardt, G.; Spruß, T.; Buschauer, A. Pharmacokinetics and tissue distribution of bovine testicular hyaluronidase and vinblastine in mice: an attempt to optimize the mode of adjuvant hyaluronidase administration in cancer chemotherapy. *Cancer Letters* **1998**, *131*, 71-84.
85. Muckenschnabel, I.; Bernhardt, G.; Spruß, T.; Dietl, B.; Buschauer, A. Quantitation of hyaluronidases by the Morgan-Elson reaction: comparison of the enzyme activities in the plasma of tumor patients and healthy volunteers. *Cancer Letters* **1998**, *131*, 13-20.
86. Schulze, F. R.; Buschauer, A.; Schunack, W. Combined histamine H<sub>1</sub>/H<sub>2</sub> receptor antagonists: Part I. Pharmacological hybrids with pheniramine- and roxatidine-like substructures. *European Journal of Pharmaceutical Sciences* **1998**, *6*, 177-186.
87. Schuster, A.; Bernhardt, G.; Eibler, E.; Buschauer, A.; Hesselink, W. Chiral separation of 3-phenyl-3-(2-pyridyl)propylamines, and analogous guanidines and guanidine-N-carboxylic acid esters with HPLC and CZE. *Journal of Chromatography A* **1998**, *793*, 77-90.
88. Schuster, A.; Bollwein, S.; Uffrecht, A.; Krey, V.; Götte, C.; Bernhardt, G.; Buschauer, A. Stereochemical Investigations on Intermediates for the Synthesis of Histamine H<sub>2</sub> Receptor

Agonists and Neuropeptide Y Y<sub>1</sub> Antagonists: Chiral Separation of Phenyl(pyridyl)alkanoic Acids by HPLC and CE. *Sci. Pharm* **1998**, *66*, 263-278.

89. Wolf, C.; Schulze, F. R.; Buschauer, A.; Schunack, W. Combined histamine H<sub>1</sub>/H<sub>2</sub> receptor antagonists: Part II. Pharmacological hybrids with pheniramine- and tiotidine-like substructures. *European Journal of Pharmaceutical Sciences* **1998**, *6*, 187-196.
90. Dove, S.; Buschauer, A. Improved Alignment by Weighted Field Fit in CoMFA of Histamine H<sub>2</sub> Receptor Agonistic Imidazolylpropylguanidines. *Quant. Struct.-Act. Relat.* **1999**, *18*, 329-341.
91. Meister, A.; Bernhardt, G.; Christoffel, V.; Buschauer, A. Antispasmodic Activity of Thymus vulgaris, Extract on the Isolated Guinea-Pig Trachea: Discrimination Between Drug and Ethanol Effects. *Planta Med* **1999**, *1999*, 512-516.
92. Moser, C.; Bernhardt, G.; Buschauer, A. Efficient Transfection of Human Endometrial Cancer (HEC-1B) Cells with FuGENE<sup>TM</sup> 6 Transfection Reagent. *biochemica* **1999**, *1/1999*, 26-27.
93. Aiglstorfer, I.; Hendrich, I.; Moser, C.; Bernhardt, G.; Dove, S.; Buschauer, A. Structure-Activity Relationships of Neuropeptide Y Y<sub>1</sub> Receptor Antagonists Related to BIBP 3226. *Bioorganic & Medicinal Chemistry Letters* **2000**, *10*, 1597-1600.
94. Buschauer, A.; Bernhardt, G.; Dove, S. NPY-Rezeptoren als Zielstrukturen für neue Arzneistoffe. *Pharmazeutische Zeitung* **2000**, *24*, 11-18.
95. Dove, S.; Michel, M. C.; Knieps, S.; Buschauer, A. Pharmacology and quantitative structure-activity relationships of imidazolylpropylguanidines with mepyramine-like substructures as non-peptide neuropeptide Y Y<sub>1</sub> receptor antagonists. *Can. J. Physiol. Pharmacol* **2000**, *78*, 108-115.
96. Moser, C.; Bernhardt, G.; Michel, J.; Schwarz, H.; Buschauer, A. Cloning and functional expression of the hNPY Y<sub>5</sub> receptor in human endometrial cancer (HEC-1B) cells. *Can J. Physiol. Pharmacol* **2000**, *78*, 134-142.
97. Zabel, M.; Breu, J.; Rau, F.; Range, K.-J.; Krey, V.; Uffrecht, A.; Buschauer, A. Absolute configuration of (-)-4-(3,4-dichlorophenyl)-4-(2-pyridyl)butanoic acid: essential information to determine crucial steric feature of arpromidine-type histamine H<sub>2</sub> receptor agonists. *Acta Crystallographica Section C* **2000**, *56*, 250-251.
98. Bischoff, A.; Püttmann, K.; Kötting, A.; Moser, C.; Buschauer, A.; Michel, M. C. Limited signal transduction repertoire of human Y<sub>5</sub> neuropeptide Y receptors expressed in HEC-B cells. *Peptides* **2001**, *22*, 387-394.
99. Kelley, M. T.; Bürckstümmer, T.; Wenzel-Seifert, K.; Dove, S.; Buschauer, A.; Seifert, R. Distinct interaction of human and guinea pig histamine H<sub>2</sub>-Receptor with guanidine-type agonists. *Molecular Pharmacology* **2001**, *60*, 1210-1225.
100. Schuster, A.; Götte, C.; Bernhardt, G.; Buschauer, A. Chiral separation of pheniramine-like 3-phenyl-3-heteroarylpropylamines by CE and HPLC methods. *Chirality* **2001**, *13*, 285-293.
101. Vogelhuber, W.; Rutunno, P.; Magni, E.; Gazzaniga, A.; Spruss, T.; Bernhardt, G.; Buschauer, A.; Goepferich, A. Programmable biodegradable implants. *Journal of Controlled Release* **2001**, *73*, 75-88.
102. Wenzel-Seifert, K.; Kelley, M. T.; Buschauer, A.; Seifert, R. Similar apparent constitutive activity of human histamine H<sub>2</sub>-receptor fused to long and short splice variants of Gsa. *Journal of Pharmacology and Experimental Therapeutics* **2001**, *299*, 1013-1020.

103. Fellner, S.; Bauer, B.; Miller, D. S.; Schaffrick, M.; Fankhänel, M.; Spruß, T.; Bernhardt, G.; Graeff, C.; Färber, L.; Gschaidmeier, H.; Buschauer, A.; Fricker, G. Transport of paclitaxel (Taxol) across the blood-brain barrier in vitro and in vivo. *The Journal of Clinical Investigation* **2002**, *110*, 1309-1318.
104. Parker, S. L.; Parker, M. S.; Lundell, I.; Balasubramaniam, A.; Buschauer, A.; Kane, J. K.; Yalcin, A.; Berglund, M. M. Agonist internalization by cloned Y1 neuropeptide Y (NPY) receptor in Chinese hamster ovary cells shows strong preference for NPY, endosome-linked entry and fast receptor recycling. *Regulatory Peptides* **2002**, *107*, 49-62.
105. Vogelhuber, W.; Spruß, T.; Bernhardt, G.; Buschauer, A.; Göpferich, A. Efficacy of BCNU and paclitaxel loaded subcutaneous implants in the interstitial chemotherapy of U-87 MG human glioblastoma xenografts. *International Journal of Pharmaceutics* **2002**, *238*, 111-121.
106. Weiss, T. S.; Bernhardt, G.; Buschauer, A.; Thasler, W. E.; Dolgner, D.; Zirngibl, H.; Jauch, K.-W. Polyamine levels of human colorectal adenocarcinomas are correlate with tumor stage and grade. *International Journal of Colorectal Disease* **2002**, *17*, 381-387.
107. Li, L.; Kracht, J.; Peng, S.; Bernhardt, G.; Buschauer, A. Synthesis and pharmacological activity of fluorescent histamine H1 receptor antagonists related to mepyramine. *Bioorganic & Medicinal Chemistry Letters* **2003**, *13*, 1245-1248.
108. Li, L.; Kracht, J.; Peng, S.; Bernhardt, G.; Elz, S.; Buschauer, A. Synthesis and pharmacological activity of fluorescent histamine H2 receptor antagonists related to potentidine. *Bioorganic & Medicinal Chemistry Letters* **2003**, *13*, 0960-894.
109. Li, L.; Mayer, M.; Schneider, E.; Schreiber, E.; Bernhardt, G.; Peng, S.; Buschauer, A. Preparation of fluorescent nonpeptidic neuropeptide Y receptor ligands: analogues of the quinazoline-type anti-obesity Y5 antagonist CGP 71683A. *Arch. Pharm.* **2003**, *336*, 585-590.
110. Oettl, M.; Hoechstetter, J.; Asen, I.; Bernhardt, G.; Buschauer, A. Comparative characterization of bovine testicular hyaluronidase and a hyaluronate lyase from *Streptococcus agalactiae* in pharmaceutical preparations. *European Journal of Pharmaceutical Sciences* **2003**, *18*, 267-277.
111. Parker, S. L.; Parker, M. S.; Buschauer, A.; Balasubramaniam, A. Ligand internalization by cloned neuropeptide Y Y5 receptors excludes Y2 and Y4 receptor-selective peptides. *European Journal of Pharmacology* **2003**, *474*, 31-42.
112. Seifert, R.; Wenzel-Seifert, K.; Bürckstümmer, T.; Pertz, H. H.; Schunack, W.; Dove, S.; Buschauer, A.; Elz, S. Multiple differences in agonist and antagonist pharmacology between human and guinea pig histamine H1-receptor. *Journal of Pharmacology and Experimental Therapeutics* **2003**, *305*, 1104-1115.
113. Botzki, A.; Rigden, D. J.; Braun, S.; Nukui, M.; Salmen, S.; Hoechstetter, J.; Bernhardt, G.; Dove, S.; Buschauer, A.; Jedrzejas, M. J. L-ascorbic acid-6-hexadecanoate, a potent hyaluronidase inhibitor: X-ray structure and molecular modeling of enzyme-inhibitor complexes. *The Journal of Biological Chemistry* **2004**, *279*, 45990-45997.
114. Brennauer, A.; Dove, S.; Buschauer, A., Structure-Activity Relationships of Nonpeptide Neuropeptide Y Receptor Antagonists. In *Neuropeptide Y and Related Peptides*, Michel, M. C., Ed. Springer: Heidelberg, 2004; Vol. 162, pp 505-546.
115. Dove, S.; Elz, S.; Seifert, R.; Buschauer, A. Structure-Activity Relationships of Histamine H<sub>2</sub> Receptor Ligands. *Mini-Rev. Med. Chem.* **2004**, *4*, 941-954.



116. Gürtler, U.; Fuchs, P.; Stangelmayer, A.; Bernhardt, G.; Buschauer, A.; Spruss, T. Construction and validation of a microprocessor controlled extracorporeal circuit in rats for the optimization of isolated limb perfusion. *Archiv der Pharmazie* **2004**, *33*, 672-681.
117. Kießling, S.; Müller-Newen, G.; Leeb, S. N.; Hausmann, M.; Rath, H. C.; Strater, J.; Spottl, T.; Schlottmann, K.; Grossmann, J.; Montero-Julian, F. A.; Schölmerich, J.; Andus, T.; Buschauer, A.; Heinrich, P. C.; Rogler, G. Functional Expression of the Interleukin-11 Receptor  $\alpha$ -Chain and Evidence of Antiapoptotic Effects in Human Colonic Epithelial Cells. *The Journal of Biological Chemistry* **2004**, *279*, 10304-10315.
118. Botzki, A.; Salmen, S.; Bernhardt, G.; Buschauer, A.; Dove, S. Structure-Based Design Of Bacterial Hyaluronan Lyase Inhibitors. *QSAR & Combinatorial Science* **2005**, *24*, 458-469.
119. Salmen, S.; Hoehstetter, J.; Käsbauer, C.; Paper, D. H.; Bernhardt, G.; Buschauer, A. Sulphated Oligosaccharides as Inhibitors of Hyaluronidases from Bovine Testis, Bee Venom and Streptococcus agalactiae. *Planta Med.* **2005**, *71*, 727-732.
120. Gross, D.; Bernhardt, G.; Buschauer, A. Platelet-derived growth factor receptor independent proliferation of human glioblastoma cells: selective tyrosine kinase inhibitors lack antiproliferative activity. *Journal of Cancer Research and Clinical Oncology* **2006**, *132*, 589-599.
121. Rigden, D. J.; Botzki, A.; Nukui, M.; Mewbourne, R. B.; Lamani, E.; Braun, S.; von Angerer, E.; Bernhardt, G.; Dove, S.; Buschauer, A.; Jedrzejas, M. J. Design of new benzoxazole-2-thione derived inhibitors of Streptococcus pneumoniae hyaluronan lyase: structure of a complex with a 2-phenylindole. *Glycobiology* **2006**, *16*, 757-765.
122. Schneider, E.; Mayer, M.; Ziemek, R.; Li, L.; Hutzler, C.; Bernhardt, G.; Buschauer, A. A Simple and Powerful Flow Cytometric Method for the Simultaneous Determination of Multiple Parameters at G-Protein-coupled Receptor Subtypes. *ChemBioChem* **2006**, *7*, 1400-1409.
123. Spickenreither, M.; Braun, S.; Bernhardt, G.; Dove, S.; Buschauer, A. Novel 6-O-acylated vitamin C derivatives as hyaluronidase inhibitors with selectivity for bacterial lyases. *Bioorganic & Medicinal Chemistry Letters* **2006**, *16*, 5313-5316.
124. Wabnitz, T. C.; Rizzo, S.; Götte, C.; Buschauer, A.; Benincori, T.; Reiser, O. Enantioselective hydrogenation of diaryl-substituted  $\alpha,\beta$ -unsaturated nitriles. *Tetrahedron Letters* **2006**, *47*, 3733-3736.
125. Xie, S.-X.; Ghorai, P.; Ye, Q.-Z.; Buschauer, A.; Seifert, R. Probing Ligand-Specific Histamine H1- and H2-Receptor Conformations with NG-Acylated Imidazolylpropylguanidines. *The Journal of Pharmacology and Experimental Therapeutics* **2006**, *317*, 139-146.
126. Xie, S.-X.; Kraus, A.; Ghorai, P.; Ye, Q.-Z.; Elz, S.; Buschauer, A.; Seifert, R. N1-(3-Cyclohexylbutanoyl)-N2-[3-(1H-imidazol-4-yl)propyl]guanidine (UR-AK57), a Potent Partial Agonist for the Human Histamine H1- and H2- Receptors. *Journal of Pharmacology and Experimental Therapeutics* **2006**, *317*, 1262-1268.
127. Xie, S.-X.; Petrache, G.; Schneider, E.; Ye, Q.-Z.; Bernhardt, G.; Seifert, R.; Buschauer, A. Synthesis and pharmacological characterization of novel fluorescent histamine H2-receptor ligands derived from aminopotentialidine. *Bioorganic & Medicinal Chemistry Letters* **2006**, *16*, 3886-3890.
128. Ziemek, R.; Brennauer, A.; Schneider, E.; Cabrele, C.; Beck-Sickinger, A. G.; Bernhardt, G.; Buschauer, A. Fluorescence- and luminescence-based methods for the determination of affinity and activity of neuropeptide Y(2) receptor ligands. *European Journal of Pharmacology* **2006**, *551*, 10-8.

129. Brennauer, A.; Keller, M.; Freund, M.; Bernhardt, G.; Buschauer, A. Decomposition of 1-(ω-aminoalkanoyl)guanidines under alkaline conditions. *Tetrahedron Lett.* **2007**, *48*, 6996-6999.
130. Egger, M.; Li, X.; Müller, C.; Bernhardt, G.; Buschauer, A.; König, B. Tariquidar analogues: synthesis by Cu(I)-catalysed N/O-aryl coupling and inhibitory activity against the ABCB1 transporter. *European Journal of Organic Chemistry* **2007**, *2007*, 2643-2649.
131. Hofinger, E. S. A.; Bernhardt, G.; Buschauer, A. Kinetics of Hyal1 and PH-20 hyaluronidases: comparison of minimal substrates and analysis of the transglycosylation reaction. *Glycobiology* **2007**, *17*, 963-971.
132. Hofinger, E. S. A.; Spickenreither, M.; Oschmann, J.; Bernhardt, G.; Rudolph, R.; Buschauer, A. Recombinant human hyaluronidase Hyal-1: insect cells versus E. coli as expression system and identification of low molecular weight inhibitors. *Glycobiology* **2007**, *17*, 444-453.
133. Müller, C.; Gross, D.; Sarli, V.; Gartner, M.; Giannis, A.; Bernhardt, G.; Buschauer, A. Inhibitors of kinesin Eg5: antiproliferative activity of monastrol analogues against human glioblastoma cells. *Cancer Chemotherapy and Pharmacology* **2007**, *59*, 157-164.
134. Preuss, H.; Ghorai, P.; Kraus, A.; Dove, S.; Buschauer, A.; Seifert, R. Point Mutations in the Second Extracellular Loop of the Histamine H<sub>2</sub> Receptor do not affect the Species-Selective Activity of Guanidine-Type Agonists. *Naunyn Schmiedebergs Arch. Pharmacol.* **2007**, *376*, 253-264.
135. Preuss, H.; Ghorai, P.; Kraus, A.; Dove, S.; Buschauer, A.; Seifert, R. Mutations of Cys-17 and Ala-271 in the Human Histamine H<sub>2</sub> Receptor Determine the Species Selectivity of Guanidine-Type Agonists and Increase Constitutive Activity. *Journal of Pharmacology and Experimental Therapeutics* **2007**, *321*, 975-982.
136. Preuss, H.; Ghorai, P.; Kraus, A.; Dove, S.; Buschauer, A.; Seifert, R. Constitutive Activity and Ligand Selectivity of Human, Guinea Pig, Rat, and Canine Histamine H<sub>2</sub> Receptors. *Journal of Pharmacology and Experimental Therapeutics* **2007**, *321*, 983-995.
137. Schneider, E.; Keller, M.; Brennauer, A.; Hoefelschweiger, B. K.; Gross, D.; Wolfbeis, O. S.; Bernhardt, G.; Buschauer, A. Synthesis and Characterization of the First Fluorescent Nonpeptide NPY Y1 Receptor Antagonist. *ChemBioChem* **2007**, *8*, 1981-1988.
138. Xie, S.-X.; Schalkhauser, F.; Ye, Q.-Z.; Seifert, R.; Buschauer, A. Effects of Impromidine- and Arpromidine-Derived Guanidines on Recombinant Human and Guinea Pig Histamine H<sub>1</sub> and H<sub>2</sub> Receptors. *Archiv der Pharmazie* **2007**, *340*, 9-16.
139. Ziemek, R.; Schneider, E.; Kraus, A.; Cabrele, C.; Beck-Sickinger, A. G.; Bernhardt, G.; Buschauer, A. Determination of affinity and activity of ligands at the human neuropeptide Y Y4 receptor by flow cytometry and aequorin luminescence. *Journal of Receptors and Signal Transduction* **2007**, *27*, 217-233.
140. Dove, S.; Seifert, R.; Elz, S.; Buschauer, A. Frontiers in medicinal chemistry in Regensburg. *ChemMedChem* **2008**, *3*, 1181-1184.
141. Ghorai, P.; Kraus, A.; Keller, M.; Götte, C.; Igel, P.; Schneider, E.; Schnell, D.; Bernhardt, G.; Dove, S.; Zabel, M.; Elz, S.; Seifert, R.; Buschauer, A. Acylguanidines as bioisosteres of guanidines: N(G)-acylated imidazolylpropylguanidines, a new class of histamine H<sub>2</sub> receptor agonists. *J. Med. Chem.* **2008**, *51*, 7193-7204.
142. Hofinger, E. S. A.; Hoehstetter, J.; Oetl, M.; Bernhardt, G.; Buschauer, A. Isoenzyme-specific differences in the degradation of hyaluronic acid by mammalian-type hyaluronidases. *Glycoconjugate Journal* **2008**, *25*, 101-109.

143. Hubensack, M.; Müller, C.; Höcherl, H.; Fellner, S.; Spruss, T.; Bernhardt, G.; Buschauer, A. Effect of the ABCB1 modulators elacridar and tariquidar on the distribution of paclitaxel in nude mice. *Journal of Cancer Research and Clinical Oncology* **2008**, *134*, 597-607.
144. Keller, M.; Pop, N.; Hutzler, C.; Beck-Sickinger, A. G.; Bernhardt, G.; Buschauer, A. Guanidine - acylguanidine bioisosteric approach in the design of radioligands: Synthesis of a tritium-labeled N(G)-propionylargininamide ([<sup>3</sup>H]UR-MK114) as a highly potent and selective neuropeptide Y Y1 receptor antagonist. *J. Med. Chem.* **2008**, *51*, 8168-8172.
145. Weiss, S.; Keller, M.; Bernhardt, G.; Buschauer, A.; König, B. Modular synthesis of non-peptidic bivalent NPY Y(1) receptor antagonists. *Bioorganic & Medicinal Chemistry* **2008**, *16*, 9858-9866.
146. Igel, P.; Geyer, R.; Straßer, A.; Dove, S.; Seifert, R.; Buschauer, A. Synthesis and structure-activity relationships of cyanoguanidine-type and structurally related histamine H(4) receptor agonists. *J. Med. Chem.* **2009**, *52*, 6297-6313.
147. Igel, P.; Schneider, E.; Schnell, D.; Elz, S.; Seifert, R.; Buschauer, A. N(G)-Acylated imidazolylpropylguanidines as potent histamine H4 receptor agonists: selectivity by variation of the N(G)-substituent. *J. Med. Chem.* **2009**, *52*, 2623-2627.
148. Igel, P.; Schnell, D.; Bernhardt, G.; Seifert, R.; Buschauer, A. Tritium-labeled N1-[3-(1H-imidazol-4-yl)propyl]-N2-propionylguanidine ([<sup>3</sup>H]UR-PI294), a high affinity histamine H3 and H4 receptor radioligand. *ChemMedChem* **2009**, *4*, 225-231.
149. Keller, M.; Teng, S.; Bernhardt, G.; Buschauer, A. Bivalent argininamide-type neuropeptide Y Y1 antagonists do not support the hypothesis of receptor dimerisation. *ChemMedChem* **2009**, *4*, 1733-1745.
150. Kraus, A.; Ghorai, P.; Birnkammer, T.; Schnell, D.; Elz, S.; Seifert, R.; Dove, S.; Bernhardt, G.; Buschauer, A. N(G)-Acylated aminothiazolylpropylguanidines as potent and selective histamine H2 receptor agonists. *ChemMedChem* **2009**, *4*, 232-240.
151. Kühnle, M.; Egger, M.; Müller, C.; Mahringer, A.; Bernhardt, G.; Fricker, G.; König, B.; Buschauer, A. Potent and selective inhibitors of breast cancer resistance protein (ABCG2) derived from the p-glycoprotein (ABCB1) modulator tariquidar. *J. Med. Chem.* **2009**, *52*, 1190-1197.
152. Ghorai, P.; Kraus, A.; Birnkammer, T.; Geyer, R.; Bernhardt, G.; Dove, S.; Seifert, R.; Elz, S.; Buschauer, A. Chiral N(G)-acylated hetarylpropylguanidine-type histamine H2 receptor agonists do not show significant stereoselectivity. *Bioorganic & Medicinal Chemistry Letters* **2010**, *20*, 3173-3176.
153. Hild, W.; Pollinger, K.; Caporale, A.; Cabrele, C.; Keller, M.; Pluym, N.; Buschauer, A.; Rachel, R.; Tessmar, J.; Breunig, M.; Goepferich, A. G protein-coupled receptors function as logic gates for nanoparticle binding and cell uptake. *Proceedings of the National Academy of Sciences USA: PNAS* **2010**, *107*, 10667-10672.
154. Igel, P.; Dove, S.; Buschauer, A. Histamine H4 receptor agonists. *Bioorganic & Medicinal Chemistry Letters* **2010**, *20*, 7191-7199.
155. Kleinmaier, R.; Igel, P.; Keller, M.; Buschauer, A.; Gschwind, R. M. Conformations, Conformational Preferences, and Conformational Exchange of N'-Substituted N-Acylguanidines: Intermolecular Interactions Hold the Key. *J. Am. Chem. Soc.* **2010**, *132*, 11223-11233.

156. Weiss, S.; Keller, M.; Bernhardt, G.; Buschauer, A.; König, B. N(G)-Acyl-argininamides as NPY Y (1) receptor antagonists: Influence of structurally diverse acyl substituents on stability and affinity. *Bioorganic & Medicinal Chemistry* **2010**, 6292-6304.
157. Braun, S.; Botzki, A.; Salmen, S.; Textor, C.; Bernhardt, G.; Dove, S.; Buschauer, A. Design of benzimidazole- and benzoxazole-2-thione derivatives as inhibitors of bacterial hyaluronan lyase. *Eur. J. Med. Chem.* **2011**, 46, 4419-4429.
158. Brunskole, I.; Strasser, A.; Seifert, R.; Buschauer, A. Role of the second and third extracellular loops of the histamine H4 receptor in receptor activation. *Naunyn-Schmiedeberg's Archives of Pharmacology* **2011**, 384, 301-317.
159. Geyer, R.; Buschauer, A. Synthesis and histamine H3 and H4 receptor activity of conformationally restricted cyanoguanidines related to UR-PI376. *Archiv der Pharmazie* **2011**, 344, 775-785.
160. Keller, M.; Bernhardt, G.; Buschauer, A. [3H]UR-MK136 - a highly potent and selective radioligand for neuropeptide Y Y1 receptors. *ChemMedChem* **2011**, 6, 1566-1571.
161. Keller, M.; Erdmann, D.; Teng, S.; Pop, N.; Pluym, N.; Bernhardt, G.; Buschauer, A. Red-fluorescent argininamide-type NPY Y(1) receptor antagonists as pharmacological tools. *Bioorganic & Medicinal Chemistry* **2011**, 19, 2859-2878.
162. Ochoa Puentes, C.; Höcherl, P.; Kühnle, M.; Bauer, S.; Kürger, K.; Bernhardt, G.; Buschauer, A.; König, B. Solid phase synthesis of tariquidar-related modulators of ABC transporters preferring breast cancer resistance protein (ABCG2). *Bioorganic & Medicinal Chemistry Letters* **2011**, 21, 3654-3657.
163. Pluym, N.; Brennauer, A.; Keller, M.; Ziemek, R.; Pop, N.; Bernhardt, G.; Buschauer, A. Application of the guanidine – acylguanidine bioisosteric approach to argininamide-type NPY Y2 receptor antagonists. *ChemMedChem* **2011**, 6, 1727-1738.
164. Pop, N.; Igel, P.; Brennauer, A.; Cabrele, C.; Bernhardt, G.; Seifert, R.; Buschauer, A. Functional reconstitution of human neuropeptide Y (NPY) Y2 and Y4 receptors in Sf9 insect cells. *Journal of Receptors and Signal Transduction* **2011**, 31, 271-285.
165. Schnell, D.; Brunskole, I.; Ladova, K.; Schneider, E. H.; Igel, P.; Dove, S.; Buschauer, A.; Seifert, R. Expression and functional properties of canine, rat and murine histamine H4-receptors in Sf9 insect cells. *Naunyn-Schmiedeberg's Archives of Pharmacology* **2011**, 383, 457-470.
166. Seifert, R.; Schneider, E. H.; Dove, S.; Brunskole, I.; Neumann, D.; Strasser, A.; Buschauer, A. Paradoxical stimulatory effects of the "standard" histamine H4-receptor antagonist JNJ7777120: The H4-receptor joins the club of 7TM receptors exhibiting functional selectivity. *Molecular Pharmacology* **2011**, 79, 631-638.
167. Weiss, S.; Bernhardt, G.; Buschauer, A.; König, B. Synthesis and characterization of DMAP-Modified NPY Y1 receptor antagonists as acyl-transfer catalysts. *Collection of Czechoslovak chemical communications* **2011**, 76, 763 -780.
168. Bernat, V.; Heinrich, M.; Baumeister, P.; Buschauer, A.; Tschammer, N. Synthesis and application of the first radioligand targeting the allosteric binding pocket of chemokine receptor CXCR3. *ChemMedChem* **2012**, 7, 1481-1489.
169. Birnkammer, T.; Spickenreither, A.; Brunskole, I.; Lopuch, M.; Kagermeier, N.; Bernhardt, G.; Dove, S.; Seifert, R.; Elz, S.; Buschauer, A. The bivalent ligand approach leads to highly potent

- and selective acylguanidine-type histamine H<sub>2</sub> receptor agonists. *J. Med. Chem.* **2012**, *55*, 1147-1160.
170. Grundmann, M.; Rothenhöfer, M.; Bernhardt, G.; Buschauer, A.; Matysik, F.-M. Fast counter-electroosmotic capillary electrophoresis-time-of-flight mass spectrometry of hyaluronan oligosaccharides. *Analytical and Bioanalytical Chemistry : Anal. Bioanal. Chem.* **2012**, *402*, 2617-2623.
  171. Löber, S.; Hübner, H.; Buschauer, A.; Sanna, F.; Argiolas, A.; Melis, M. R.; Gmeiner, P. Novel azulene derivatives for the treatment of erectile dysfunction. *Bioorganic & medicinal chemistry letters* **2012**, *22*, 7151-7154.
  172. Memminger, M.; Keller, M.; Lopuch, M.; Pop, N.; Bernhardt, G.; von Angerer, E.; Buschauer, A. The Neuropeptide Y Y<sub>1</sub> receptor: a diagnostic marker? Expression in MCF-7 breast cancer cells is down-regulated by antiestrogens in vitro and in xenografts. *PLoS ONE* **2012**, *7*, e51032.
  173. Reher, T. M.; Neumann, D.; Buschauer, A.; Seifert, R. Incomplete activation of human eosinophils via the histamine H<sub>4</sub>-receptor: Evidence for ligand-specific receptor conformations. *Biochemical Pharmacology* **2012**, *84*, 192-203.
  174. Rothenhöfer, M.; Scherübl, R.; Bernhardt, G.; Heilmann, J.; Buschauer, A. Qualitative and quantitative analysis of hyaluronan oligosaccharides with high performance thin layer chromatography using reagent-free derivatization on amino-modified silica and electrospray ionization-quadrupole time-of-flight mass spectrometry coupling on normal phase. *Journal of chromatography. A* **2012**, *1248*, 169-77.
  175. Bauer, S.; Ochoa Puentes, C.; Sun, Q.; Bause, M.; Bernhardt, G.; König, B.; Buschauer, A. Quinoline carboxamide-type ABCG2 modulators: Indole and quinoline moieties as anilide replacements. *ChemMedChem* **2013**, *8*, 1773-1778.
  176. Berlicki, L.; Kaske, M.; Gutierrez-Abad, R.; Bernhardt, G.; Illa, O.; Ortuño, R.; Cabrele, C.; Buschauer, A.; Reiser, O. Replacement of Thr32 and Gln34 in the C-terminal neuropeptide Y fragment 25-36 by cis-cyclobutane- and cis-cyclopentane  $\beta$ -amino acids shifts selectivity toward the Y<sub>4</sub> receptor. *J. Med. Chem.* **2013**, *56*, 8422-8431.
  177. Bodensteiner, J.; Baumeister, P.; Geyer, R.; Buschauer, A.; Reiser, O. Synthesis and pharmacological characterization of new tetrahydrofuran based compounds as conformationally constrained histamine receptor ligands. *Organic & biomolecular chemistry* **2013**, *11*, 4040-4055.
  178. Brunskole Hummel, I.; Kälble, S.; Burhenne, H.; Reinartz, M. T.; Schwede, F.; Buschauer, A.; Seifert, R. Dissociations in the effects of beta<sub>2</sub>-adrenergic receptor agonists on cAMP formation and superoxide production in human neutrophils: Support for the concept of functional selectivity. *PLoS One* **2013**, *8*, e64556.
  179. Dove, S.; Buschauer, A. G-Protein-gekoppelte Rezeptoren: „Sinnesorgane“ der Zellen. *Blick in die Wissenschaft* **2013**, *22*, 3-9.
  180. Keller, M.; Kaske, M.; Holzammer, T.; Bernhardt, G.; Buschauer, A. Dimeric argininamide-type neuropeptide Y receptor antagonists: chiral discrimination between Y<sub>1</sub> and Y<sub>4</sub> receptors. *Bioorganic and Medicinal Chemistry* **2013**, *21*, 6303-6322.
  181. Nordemann, U.; Wifling, D.; Schnell, D.; Bernhardt, G.; Stark, H.; Seifert, R.; Buschauer, A. Luciferase reporter gene assay on human, murine and rat histamine H<sub>4</sub> receptor orthologs: correlations and discrepancies between distal and proximal readouts. *PLoS One* **2013**, *8*, e73961.

182. Ochoa-Puentes, C.; Bauer, S.; Kühnle, M.; Bernhardt, G.; Buschauer, A.; König, B. Benzanilide – Biphenyl Replacement: A Bioisosteric Approach to Quinoline Carboxamide-type ABCG2 Modulators. *ACS Med. Chem. Lett.* **2013**, *4*, 393-396.
183. Pluym, N.; Baumeister, P.; Keller, M.; Bernhardt, G.; Buschauer, A. [3H]UR-PLN196: A Selective Nonpeptide Radioligand and Insurmountable Antagonist for the Neuropeptide Y Y2 Receptor. *ChemMedChem* **2013**, *8*, 587-593.
184. Sadek, B.; Alisch, R.; Buschauer, A.; Elz, S. Synthesis and dual histamine H1 and H2 receptor antagonist activity of cyanoguanidine derivatives. *Molecules* **2013**, *18*, 14186-14202.
185. Schreeb, A.; Łażewska, D.; Dove, S.; Buschauer, A.; Kieć-Kononiwicz, K.; Stark, H., Histamine H4 receptor ligands. In *Histamine H4 receptor: a novel drug target for immunoregulation and inflammation*, Stark, H., Ed. Versita: London, 2013; pp 21-62.
186. Seifert, R.; Strasser, A.; Schneider, E. H.; Neumann, D.; Dove, S.; Buschauer, A. Molecular and cellular analysis of human histamine receptor subtypes. *Trends in Pharmacological Sciences* **2013**, *34*, 33-58.
187. Strasser, A.; Wittmann, H.-J.; Buschauer, A.; Schneider, E. H.; Seifert, R. Species-dependent activities of GPCR ligands: Lessons from histamine receptor orthologs. *Trends in Pharmacological Sciences* **2013**, *34*, 13-32.
188. Cuboni, S.; Devigny, C.; Hoogeland, B.; Strasser, A.; Pomplun, S.; Hauger, B.; Höfner, G.; Wanner, K.; Eder, M.; Buschauer, A.; Holsboer, F.; Hausch, F. Loratadine and analogs: Discovery and preliminary SAR of inhibitors of the amino acid transporter B0AT2. *J. Med. Chem.* **2014**, *57*, 9473-9479.
189. Geyer, R.; Igel, P.; Kaske, M.; Elz, S.; Buschauer, A. Synthesis, SAR and selectivity of 2-acyl- and 2-cyano-1-hetarylalkyl-guanidines at the four histamine receptor subtypes: a bioisosteric approach. *MedChemComm* **2014**, *5*, 72-81.
190. Geyer, R.; Kaske, M.; Baumeister, P.; Buschauer, A. Synthesis and functional characterization of imbutamine analogs as histamine H3 and H4 receptor ligands. *Archiv der Pharmazie (Weinheim, Germany)* **2014**, *347*, 77-88.
191. Pollinger, K.; Hennig, R.; Bauer, S.; Breunig, M.; Tessmar, J.; Buschauer, A.; Witzgall, R.; Göpferich, A. Biodistribution of quantum dots in the kidney after intravenous injection. *Journal of Nanoscience and Nanotechnology* **2014**, *14*, 3313-3319.
192. Werner, K.; Neumann, D.; Buschauer, A.; Seifert, R. No evidence for histamine H4-receptor in human monocytes. *Journal of Pharmacology and Experimental Therapeutics* **2014**, *351*, 519-526.
193. Baumeister, P.; Erdmann, D.; Biselli, S.; Kagermeier, N.; Elz, S.; Bernhardt, G.; Buschauer, A. 3HUR-DE257: Development of a tritium-labeled squaramide-type selective histamine H2 receptor antagonist. *ChemMedChem* **2015**, *10*, 83-93.
194. Beermann, S.; Bernhardt, G.; Seifert, R.; Buschauer, A.; Neumann, D. Histamine H1- and H4-receptor signaling cooperatively regulate MAPK activation. *Biochemical Pharmacology* **2015**, *98*, 432-439.
195. Huber, S.; Antoni, F.; Schickaneder, C.; Schickaneder, H.; Bernhardt, G.; Buschauer, A. Stabilities of neutral and basic esters of bendamustine in plasma compared to the parent compound: Kinetic investigations by HPLC. *Journal of Pharmaceutical and Biomedical Analysis* **2015**, *104*, 137-143.

196. Huber, S.; Huettner, J. P.; Hacker, K.; Bernhardt, G.; König, J.; Buschauer, A. Esters of bendamustine are by far more potent cytotoxic agents than the parent compound against human sarcoma and carcinoma cells. *PLoS One* **2015**, *10*, PLoSe0133743.
197. Huber, S.; Wege, A. K.; Bernhardt, G.; Buschauer, A.; Brockhoff, G. Topotecan-induced ABCG2 expression in MCF-7 cells is associated with decreased CD24 and EpCAM expression and a loss of tumorigenicity. *Cytometry A* **2015**, *87*, 707-716.
198. Kagermeier, N.; Werner, K.; Keller, M.; Baumeister, P.; Bernhardt, G.; Seifert, R.; Buschauer, A. Dimeric carbamoylguanidine-type histamine H2 receptor ligands: A new class of potent and selective agonists. *Bioorganic & Medicinal Chemistry* **2015**, *23*, 3957-3969.
199. Keller, M.; Schindler, L.; Bernhardt, G.; Buschauer, A. Towards labeled argininamide-type NPY Y1 receptor antagonists: Identification of a favorable propionylation site in BIBO3304. *Archiv der Pharmazie* **2015**, *348*, 390-398.
200. Keller, M.; Tränkle, C.; She, X.; Pegoli, A.; Bernhardt, G.; Buschauer, A.; Read, R. W. M2 subtype preferring dibenzodiazepinone-type muscarinic receptor ligands: effect of chemical homo-dimerization on orthosteric (and allosteric?) binding. *Bioorganic & Medicinal Chemistry* **2015**, *23*, 3970-3990.
201. Keller, M.; Weiss, S.; Hutzler, C.; Kuhn, K. K.; Mollereau, C.; Dukorn, S.; Schindler, L.; Bernhardt, G.; König, B.; Buschauer, A. N(omega)-carbamoylation of the argininamide moiety: an avenue to insurmountable NPY Y1 receptor antagonists and a radiolabeled selective high affinity molecular tool ([<sup>3</sup>H]UR-MK299) with extended residence time. *J. Med. Chem.* **2015**, *58*, 8834-8849.
202. Orlando, Z.; Lengers, I.; Melzig, M. F.; Buschauer, A.; Hensel, A.; Jose, J. Autodisplay of human hyaluronidase Hyal-1 on Escherichia coli and identification of plant-derived enzyme inhibitors. *Molecules* **2015**, *20*, 15449-15468.
203. Rothenhöfer, M.; Grundmann, M.; Bernhardt, G.; Matysik, F.-M.; Buschauer, A. High performance anion exchange chromatography with pulsed amperometric detection (HPAEC-PAD) for the sensitive determination of hyaluronan oligosaccharides. *Journal of Chromatography B* **2015**, *988*, 106-115.
204. Strasser, A.; Buschauer, A. Histaminrezeptoren. *Pharmakon* **2015**, *3*, 109-116.
205. Werner, K.; Kälble, S.; Wolter, S.; Schneider, E. H.; Buschauer, A.; Neumann, D.; Seifert, R. Flow cytometric analysis with a fluorescent formyl peptide receptor ligand as a new method to study the pharmacological profile of the histamine H2-receptor. *Naunyn Schmiedebergs Archives of Pharmacology* **2015**, *388*, 1039-1052.
206. Wifling, D.; Bernhardt, G.; Dove, S.; Buschauer, A. The extracellular loop 2 (ECL2) of the human histamine H4 receptor substantially contributes to ligand binding and constitutive activity. *PLoS One* **2015**, *10*, 1-14.
207. Wifling, D.; Löffel, K.; Nordemann, U.; Strasser, A.; Bernhardt, G.; Dove, S.; Seifert, R.; Buschauer, A. Molecular determinants for the high constitutive activity of the human histamine H4 receptor: Functional studies on orthologs and mutants. *British Journal of Pharmacology* **2015**, *172*, 785-798.
208. Edalat, L.; Stegen, B.; Klumpp, L.; Haehl, E.; Schilbach, K.; Lukowski, R.; Kühnle, M.; Bernhardt, G.; Buschauer, A.; Zips, D.; Ruth, P.; Huber, S. M. BK K<sup>+</sup> channel blockade inhibits radiation-induced migration/brain infiltration of glioblastoma cells. *Oncotarget* **2016**, *7*, 14259-14278.

209. Geyer, R.; Nordemann, U.; Strasser, A.; Wittmann, H.-J.; Buschauer, A. Conformational restriction and enantioseparation increase potency and selectivity of cyanoguanidine-type histamine H4 receptor agonists. *J. Med. Chem.* **2016**, *59*, 3452-3470.
210. Keller, M.; Kuhn, K. K.; Einsiedel, J.; Hübner, H.; Biselli, S.; Mollereau, C.; Wifling, D.; Svobodova, J.; Bernhardt, G.; Cabrele, C.; Vanderheyden, P.; Gmeiner, P.; Buschauer, A. Mimicking of arginine by functionalized N $\omega$ -carbamoylated arginine as a new broadly applicable approach to labeled bioactive peptides: high affinity angiotensin, neuropeptide Y, neuropeptide FF and neurotensin receptor ligands as examples. *J. Med. Chem.* **2016**, *59*, 1925-1945.
211. Kuhn, K. K.; Ertl, T.; Dukorn, S.; Keller, M.; Bernhardt, G.; Reiser, O.; Buschauer, A. High affinity agonists of the neuropeptide Y (NPY) Y4 receptor derived from the C-terminal pentapeptide of human pancreatic polypeptide (hPP): synthesis, stereochemical discrimination and radiolabeling. *J. Med. Chem.* **2016**, *59*, 6045-6058.
212. Lieb, S.; Littmann, T.; Plank, N.; Felixberger, J.; Tanaka, M.; Schäfer, T.; Krief, S.; Elz, S.; Friedland, K.; Bernhardt, G.; Wegener, J.; Ozawa, T.; Buschauer, A. Label-free versus conventional cellular assays: functional investigations on the human histamine H1 receptor. *Pharmacological Research* **2016**, *114*, 13-26.
213. Lieb, S.; Michaelis, S.; Plank, N.; Bernhardt, G.; Buschauer, A.; Wegener, J. Label-free analysis of GPCR-stimulation: The critical impact of cell adhesion. *Pharmacological Research* **2016**, *108*, 65-74.
214. Obreque-Balboa, J.-E.; Sun, Q.; Bernhardt, G.; König, B.; Buschauer, A. Flavonoid derivatives as selective ABCC1 modulators: Synthesis and functional characterization. *Eur. J. Med. Chem.* **2016**, *109*, 124-133.
215. Dukorn, S.; Littmann, T.; Keller, M.; Kuhn, K. K.; Cabrele, C.; Baumeister, P.; Bernhardt, G.; Buschauer, A. Fluorescence- and radio-labeling of Lys4,Nle17,30hPP yields molecular tools for the NPY Y4 receptor. *Bioconjugate Chemistry* **2017**.
216. Keller, M.; Maschauer, S.; Brennauer, A.; Tripal, P.; Koglin, N.; Dittrich, R.; Bernhardt, G.; Kuwert, T.; Wester, H.-J.; Buschauer, A.; Prante, O. Prototypic <sup>18</sup>F-Labeled Argininamide-Type Neuropeptide Y Y1R Antagonists as Tracers for PET Imaging of Mammary Carcinoma. *ACS Med. Chem. Lett.* **2017**, *8*, 304-309.
217. Kuhn, K. K.; Littmann, T.; Dukorn, S.; Tanaka, M.; Keller, M.; Ozawa, T.; Bernhardt, G.; Buschauer, A. In Search of NPY Y4R Antagonists: Incorporation of Carbamoylated Arginine, Aza-Amino Acids, or d-Amino Acids into Oligopeptides Derived from the C-Termini of the Endogenous Agonists. *ACS Omega* **2017**, *2*, 3616-3631.
218. Brox, R.; Milanos, L.; Saleh, N.; Baumeister, P.; Buschauer, A.; Hofmann, D.; Heinrich, M. R.; Clark, T.; Tschammer, N. Molecular Mechanisms of Biased and Probe-Dependent Signaling at CXC-Motif Chemokine Receptor CXCR3 Induced by Negative Allosteric Modulators. *Molecular Pharmacology* **2018**, *93*, 309-322.
219. Jackson, S. M.; Manolaridis, I.; Kowal, J.; Zechner, M.; Taylor, N. M. I.; Bause, M.; Bauer, S.; Bartholomaeus, R.; Bernhardt, G.; König, B.; Buschauer, A.; Stahlberg, H.; Altmann, K.-H.; Locher, K. P. Structural basis of small-molecule inhibition of human multidrug transporter ABCG2. *Nature Structural & Molecular Biology* **2018**, *25*, 333-340.
220. Littmann, T.; Ozawa, T.; Hoffmann, C.; Buschauer, A.; Bernhardt, G. A split luciferase-based probe for quantitative proximal determination of G $\alpha_q$  signalling in live cells. *Scientific Reports* **2018**, *8*, 17179.



221. Littmann, T.; Ozawa, T.; Hoffmann, C.; Buschauer, A.; Bernhardt, G. A split luciferase-based probe for quantitative proximal determination of Gαq signalling in live cells. *Scientific Reports* **2018**, *8*, 1-10.
222. Peña-Solórzano, D.; Scholler, M.; Bernhardt, G.; Buschauer, A.; König, B.; Ochoa-Puentes, C. Tariquidar-Related Chalcones and Ketones as ABCG2 Modulators. *ACS Med. Chem. Lett.* **2018**, *9*, 854-859.
223. Pockes, S.; Wifling, D.; Keller, M.; Buschauer, A.; Elz, S. Highly Potent, Stable, and Selective Dimeric Hetarylpropylguanidine-Type Histamine H<sub>2</sub> Receptor Agonists. *ACS Omega* **2018**, *2018*, 2865-2882.
224. Yang, Z.; Han, S.; Keller, M.; Kaiser, A.; Bender, B. J.; Bosse, M.; Burkert, K.; Kögler, L. M.; Wifling, D.; Bernhardt, G.; Plank, N.; Littmann, T.; Schmidt, P.; Yi, C.; Li, B.; Ye, S.; Zhang, R.; Xu, B.; Larhammar, D.; Stevens, R. C.; Huster, D.; Meiler, J.; Zhao, Q.; Beck-Sickinger, A. G.; Buschauer, A.; Wu, B. Structural basis of ligand binding modes at the neuropeptide Y Y<sub>1</sub> receptor. *Nature* **2018**, *556*, 520-524.
225. Bartole, E.; Littmann, T.; Tanaka, M.; Ozawa, T.; Buschauer, A.; Bernhardt, G. [<sup>3</sup>H]UR-DEBa176: A 2,4-Diaminopyrimidine-Type Radioligand Enabling Binding Studies at the Human, Mouse, and Rat Histamine H<sub>4</sub> Receptors. *J. Med. Chem.* **2019**, *62*, 8338-8356.
226. Łażewska, D.; Mogilski, S.; Hagenow, S.; Kuder, K.; Głuch-Lutwin, M.; Siwek, A.; Więcek, M.; Kaleta, M.; Seibel, U.; Buschauer, A.; Filipek, B.; Stark, H.; Kieć-Kononowicz, K. Alkyl derivatives of 1,3,5-triazine as histamine H<sub>4</sub> receptor ligands. *Bioorganic & Medicinal Chemistry* **2019**, *27*, 1254-1262.
227. Littmann, T.; Buschauer, A.; Bernhardt, G. Split luciferase-based assay for simultaneous analyses of the ligand concentration- and time-dependent recruitment of β-arrestin2. *Analytical Biochemistry* **2019**, *573*, 8-16.
228. Pockes, S.; Wifling, D.; Buschauer, A.; Elz, S. Structure-Activity Relationship of Hetarylpropylguanidines Aiming at the Development of Selective Histamine Receptor Ligands. *ChemistryOpen* **2019**, *8*, 285-297.
229. Stolwijk, J. A.; Skiba, M.; Kade, C.; Bernhardt, G.; Buschauer, A.; Hübner, H.; Gmeiner, P.; Wegener, J. Increasing the throughput of label-free cell assays to study the activation of G-protein-coupled receptors by using a serial agonist exposure protocol. *Integrative Biology* **2019**, *11*, 99-108.
230. Wifling, D.; Pflieger, C.; Kaindl, J.; Ibrahim, P.; Kling, R. C.; Buschauer, A.; Gohlke, H.; Clark, T. Basal Histamine H<sub>4</sub> Receptor Activation: Agonist Mimicry by the Diphenylalanine Motif. *Chemistry – A European Journal* **2019**, *25*, 14613-14624.
231. Antoni, F.; Bause, M.; Scholler, M.; Bauer, S.; Stark, S. A.; Jackson, S. M.; Manolaridis, I.; Locher, K. P.; König, B.; Buschauer, A.; Bernhardt, G. Tariquidar-related triazoles as potent, selective and stable inhibitors of ABCG2 (BCRP). *Eur. J. Med. Chem.* **2020**, *191*.
232. Bartole, E.; Grätz, L.; Littmann, T.; Wifling, D.; Seibel, U.; Buschauer, A.; Bernhardt, G. UR-DEBa242: A Py-5-Labeled Fluorescent Multipurpose Probe for Investigations on the Histamine H<sub>3</sub> and H<sub>4</sub> Receptors. *J. Med. Chem.* **2020**, *63*, 5297-5311.
233. Biselli, S.; Alencastre, I.; Tropmann, K.; Erdmann, D.; Chen, M.; Littmann, T.; Maia, A. F.; Gomez-Lazaro, M.; Tanaka, M.; Ozawa, T.; Keller, M.; Lamghari, M.; Buschauer, A.; Bernhardt, G. Fluorescent H<sub>2</sub> Receptor Squaramide-Type Antagonists: Synthesis, Characterization, and Applications. *ACS Med. Chem. Lett.* **2020**, *11*, 1521-1528.

234. Stolwijk, J. A.; Mildner, A.-K.; Kade, C.; Skiba, M.; Bernhardt, G.; Buschauer, A.; Huebner, H.; Gmeiner, P.; Wegener, J. Stepwise Dosing Protocol for Increased Throughput in Label-Free Impedance-Based GPCR Assays. *JoVE* **2020**, DOI: 10.3791/60686
235. Biselli, S.; Bresinsky, M.; Tropmann, K.; Forster, L.; Honisch, C.; Buschauer, A.; Bernhardt, G.; Pockes, S. Pharmacological characterization of a new series of carbamoylguanidines reveals potent agonism at the H2R and D3R. *Eur. J. Med. Chem.* **2021**, *214*, 113190.
236. Tropmann, K.; Bresinsky, M.; Forster, L.; Mönnich, D.; Buschauer, A.; Wittmann, H.-J.; Hübner, H.; Gmeiner, P.; Pockes, S.; Strasser, A. Abolishing Dopamine D2long/D3 Receptor Affinity of Subtype-Selective Carbamoylguanidine-Type Histamine H2 Receptor Agonists. *J. Med. Chem.* **2021**, *64*, 8684-8709.